Papiol, S
Popovic, D
Keeser, D
Hasan, A
Schneider-Axmann, T
Degenhardt, F
Rossner, M J
Bickeböller, H
Schmitt, A
Falkai, P
Malchow, B
Article History
Received: 3 March 2017
Revised: 12 May 2017
Accepted: 17 May 2017
First Online: 27 June 2017
Competing interests
: A Hasan has been invited to scientific meetings by Lundbeck, Janssen-Cilag and Pfizer, received a paid speakership from Desitin, Otsuka and Lundbeck, and was a member of a Roche advisory board. P Falkai has been an honorary speaker for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Essex, GE Healthcare, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Servier and Takeda, and during the past 5 years, but not presently, has been a member of the advisory boards of Janssen-Cilag, AstraZeneca, Eli Lilly and Lundbeck. A Schmitt has been an honorary speaker for TAD Pharma and Roche, and a member of advisory boards for Roche. The remaining authors declare no conflict of interest.